Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpFinancial_Report.xls
10-Q - FORM 10-Q - Raptor Pharmaceutical Corpd270609d10q.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR8.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR6.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR9.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR3.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR7.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR1.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR12.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR18.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR11.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR17.htm
EX-32.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D. AND KIM R. TSUCHIMOTO - Raptor Pharmaceutical Corpd270609dex321.htm
EX-31.2 - CERTIFICATION OF KIM R. TSUCHIMOTO, CHIEF FINANCIAL OFFICER - Raptor Pharmaceutical Corpd270609dex312.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR5.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR14.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR13.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR19.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR10.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR15.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR16.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR4.htm
EX-31.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D., CHIEF EXECUTIVE OFFICER - Raptor Pharmaceutical Corpd270609dex311.htm
v2.4.0.6
Condensed Consolidated Balance Sheets (USD $)
Nov. 30, 2011
Aug. 31, 2011
ASSETS    
Cash and cash equivalents $ 24,732,255 $ 15,172,086 [1]
Restricted cash 113,336 114,468 [1]
Short-term investments 30,018,461  
Prepaid expenses and other 330,206 415,944 [1]
Total current assets 55,194,258 15,702,498 [1]
Intangible assets, net 3,214,417 3,250,917 [1]
Goodwill 3,275,403 3,275,403 [1]
Fixed assets, net 70,847 76,997 [1]
Deposits 104,906 104,906 [1]
Deferred offering costs   151,783 [1]
Total assets 61,859,831 22,562,504 [1]
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)    
Accounts payable 2,265,057 847,137 [1]
Accrued liabilities 1,658,386 2,249,254 [1]
Common stock warrant liability 25,367,694 23,575,294 [1]
Deferred rent 21,242 24,136 [1]
Capital lease liability - current 4,011 3,953 [1]
Total current liabilities 29,316,390 26,699,774 [1]
Capital lease liability - long-term 8,754 9,778 [1]
Total liabilities 29,325,144 26,709,552 [1]
Commitments and contingencies       [1]
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value, 15,000,000 shares authorized, zero shares issued and outstanding       [1]
Common stock, $0.001 par value, 150,000,000 shares authorized 47,773,488 and 35,569,188 shares issued and outstanding as at November 30, and August 31, 2011, respectively 47,773 35,569 [1]
Additional paid-in capital 121,927,944 73,817,083 [1]
Accumulated other comprehensive income (loss) (6,569) 1,904 [1]
Deficit accumulated during development stage (89,434,461) (78,001,604) [1]
Total stockholders' equity (deficit) 32,534,687 (4,147,048) [1]
Total liabilities and stockholders' equity (deficit) $ 61,859,831 $ 22,562,504 [1]
[1] Derived from the Company's audited consolidated financial statements as of August 31, 2011.